See the DrugPatentWatch profile for wegovy
How Long to Stay on Wegovy's Maintenance Dose
Wegovy (semaglutide) maintenance dose is 2.4 mg weekly, reached after gradual titration from 0.25 mg. Novo Nordisk guidelines state no fixed duration—continue as long as benefits (weight loss, health improvements) outweigh risks, under doctor supervision. Most patients stay on it long-term for sustained results, as weight regain occurs quickly after stopping.[1]
What Happens If You Stop the Maintenance Dose
Discontinuing leads to appetite rebound and average 2/3 weight regain within a year, per STEP trials. One-year trial data showed 6.9% further weight loss on continued 2.4 mg vs. 7% regain after switch to placebo.[2] Doctors often recommend lifelong use for obesity management, similar to other chronic conditions like hypertension.
Factors Your Doctor Considers for Duration
- Weight goals and response: Stay if losing ≥5% body weight and maintaining it; reassess if plateau.
- Side effects: Common issues like nausea or GI upset may prompt dose adjustment or pause, but rarely full stop.
- Health changes: Continue for comorbidities (e.g., diabetes, heart disease); taper if BMI normalizes.
- Patient preference/cost: High cost ($1,300+/month without insurance) influences decisions—some cycle off/on.
When Might You Taper or Stop
No official taper protocol, but doctors may reduce to 1.7 mg or 1.0 mg weekly before stopping to minimize rebound. Short-term use (6-12 months) for goal weight, then lifestyle maintenance is an option, though evidence shows poor long-term success without meds. Monitor A1C, lipids, and weight quarterly.[3]
Alternatives If Stopping Wegovy
Switch to similar GLP-1 drugs like Zepbound (tirzepatide, up to 22.5 mg) for potentially better weight loss (20-25% vs. Wegovy's 15%). Oral semaglutide (Rybelsus) or lower-dose Ozempic as bridges. Non-drug options: bariatric surgery for severe cases or intensive behavioral therapy, but meds outperform alone.[4]
[1] Novo Nordisk Wegovy Prescribing Information: https://www.novo-pi.com/wegovy.pdf
[2] NEJM STEP 1 Trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[3] ADA Obesity Guidelines: https://diabetesjournals.org/care/issue/47/Supplement_1
[4] FDA Zepbound Approval: https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management